Loading...

ALBT AVALON GLOBOCARE CORP Expansion Plans 8-K Filing

VLN

LBT

AVALON GLOBOCARE CORP

(ALBT)

2025 8-K

Market Update Announced

Nasdaq Compliance Notice

Merger Announcement

Filing Amendment Details

Product Launch Announcement

Equity Offerings

Debt Restructuring

Equity Offerings

Equity Offerings

Product Expansion

Equity Offerings

Asset Acquisitions

Failure to Meet Requirements

Merger of Equals

Partnership Announcement

Marketing Update

Merger Agreement

Equity Redemption

Patent Approval

Stock Exchange Agreement

Capital Structure Update

Nasdaq Compliance Regained

Marketing Program Launch

Stock Delisting

Management Change

New Development

Stock Split Announcement

Annual Meeting Results

Event Sponsorship

Change in Registrant's Cert...

Convertible Note Financing

Delisting Notice

Delisting Notice

Financial Obligation

Delisting Notice

Convertible Note Financing ...

Annual Meeting Results

New Laboratory Opening

Asset Acquisitions

Strategic Alliances

Sales Agreement with Roth C...

Financing Agreements

Acquisition of Laboratory S...

Appointment of Director

Reverse Stock Split

External Links:

Avalon GloboCare Corp. announced on July 14, 2025, that it has been granted a standard patent in Hong Kong for its CAR-T and CAR-Natural Killer cell technology, highlighting its innovation in cellular therapy.

AI Assistant

AVALON GLOBOCARE CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.